Effectiveness of buprenorphine maintenance treatment as compared to a syringe exchange program among buprenorphine misusing opioid-dependent patients

Nordic Journal of Psychiatry

Volumn 65, Issue 4, 2011, Pages 238-243

  Aalto, Mauri ^a,b   Visapää, Jukka Pekka ^c   Halme, Jukka T ^a   Fabritius, Carola ^d   Salaspuro, Mikko ^c  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d City of Helsinki   (Finland)

Author keywords

Buprenorphine; Maintenance treatment; Opioid dependence; Syringe exchange program

Indexed keywords

BUPRENORPHINE;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG MISUSE; EUROPEAN ADDICTION SEVERITY INDEX; FEMALE; FINLAND; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ABUSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPIATE ADDICTION; OPTIMAL DRUG DOSE; PROSPECTIVE STUDY; QUALITY OF LIFE; SCORING SYSTEM; STRUCTURED INTERVIEW; SYRINGE; SYRINGE EXCHANGE PROGRAM; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; AMBULATORY CARE; ANALGESICS, OPIOID; BUPRENORPHINE; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; NEEDLE-EXCHANGE PROGRAMS; OPIOID-RELATED DISORDERS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051529638     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2010.531762     Document Type: Article

References (21)

1. Connock M, Juarez-Garzia A, Jowett S, Frew E, Liu Z, Taylor RJ, et al. Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health Tecnol Assess 2007;11:1-171.
2. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, 2008, Issue 2. Art. No.: CD002207. DOI: 10.1002/14651858. CD002207.pub3. (Pubitemid 351807246)
3. Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007a;88:75-8. (Pubitemid 46400304)
4. Alho H, Vuori E, Holopainen A. Laittomasta opiaattikorvaushoidosta p ä ä st ä v ä laillisen hoidon piiriin. [From illegal opiate use to maintenance treatment]. In Finnish. Duodecim 2007b;123:757-59.
5. Ksobiech K. A meta-analysis of needle sharing, lending, and borrowing behaviours of needle exchange program attenders. AIDS Educ Prev 2003:15;257-68. (Pubitemid 36791290)
6. Stolz JA, Wood E, Small W, Li K, Tyndall M, Montaner J, Kerr T. Changes in injecting practices associated with the use of a medically supervised safer injection facility. J Public Health 2007;29:35-9.
7. McLellan AT, Luborsky L, Woody GE, O'Brian CP. An improved diagnostic evaluation instrument of substance abuse patients: The Addiction Severity Index. J Nerv Ment Dis 1980;168:26-33. (Pubitemid 10187569)
8. Blanken P, Hendriks V, Pozzi G, Tempesta E, Hartgers C, Koeter M, et al. European Addiction Severity Index (EuropASI). A guide to training and administering EuropASI interviews. 1994, Evaluation Instrument Bank.
9. Gossop M, Darke S, Griffi ths P, Hando J, Powis B, Hall W, Strang J. The Severity of Dependence Scale (SDS): Psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 1995;90;607-14.
10. Hodgins DC, El-Guebaly N. More data on the Addiction Severity Index. Reliability and validity with mentally ill substance abusers. J Nerv Ment Dis 1992;180:197-201.
11. Leonhard CL, Mulvey K, Gastfriend DR, Schwartz M. The Addiction Severity Index: A fi eld study of internal consistency and validity. J Subst Abuse Treat 2000;18:129-35. (Pubitemid 30123096)
12. Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-fi ve years of evaluation. Clin Psych Rev 1988;8:77-100. (Pubitemid 18045797)
13. Lykke J, Hesse M, Austin SF, Oestrich I. Validity of the BPRS, the BDI and the BAI in dual diagnosis patients. Addict Behav 2008;33:292-300. (Pubitemid 350253175)
14. Wittchen HU, Apelt SM, Soyka M, Gastpar M, Backmund M, Gölz J, et al. Feasibility and outcome of substitution treatment of heroindependent patients in specialized substitution centers and primarycare facilities in Germany: A naturalistic study in 2694 patients. Drug Alcohol Depend 2008;95;245-57.
15. Soeffi ng JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA. Buprenorphine maintenance treatment in a primary care setting: Outcomes at 1 year. J Subs Abuse Med 2009; 37:426-30 .
16. Lee JD, Grossman E, DiRocco D, Gourevitch MN. Home buprenorphine/ naloxone induction in primary care. J Gen Intern Med 2009;24:226-32.
17. Simoens S, Matheson C, Bond C, Inkster K, Ludbrook A. The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. Br J Gen Pract 2005; 55 :139 - 4 6.
18. Gibson A, Degenhardt L, Mattick RP, Ali R, White J, O'Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction 2008;103:462-8. (Pubitemid 351208102)
19. Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. Drug Alcohol Depend 2009;105:9-15.
20. Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009;104:1193-200.
21. Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): A national prospective cross-registry study. Drug Alcohol Depend 2008;94:151-7.